Trials / Completed
CompletedNCT04213677
Dapagliflozin Efficacy and Action in PCOS
Efficacy and Safety of Dapagliflozin in Polycystic Ovary Syndrome: a Multicentre, Randomized, Placebo-controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of dapagliflozin on improving insulin resistance and hyperandrogenemia in obesity women with polycystic ovary syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education. |
| DRUG | Placebo | Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education. |
Timeline
- Start date
- 2020-03-20
- Primary completion
- 2022-10-01
- Completion
- 2022-11-01
- First posted
- 2019-12-30
- Last updated
- 2023-01-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04213677. Inclusion in this directory is not an endorsement.